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Receptora b s t r a c t
Adenosine triphosphate (ATP) plays a fundamental role in cellular communication, with its extracel-
lular accumulation triggering purinergic signaling cascades in a diversity of cell types. While the
roles for purinergic signaling in health and disease have been well established, identiﬁcation and
differentiation of the speciﬁc mechanisms controlling cellular ATP release is less well understood.
Multiple mechanisms have been proposed to regulate ATP release with connexin (Cx) hemichannels
and pannexin (Panx) channels receiving major focus. However, segregating the speciﬁc roles of
Panxs and Cxs in ATP release in a plethora of physiological and pathological contexts has remained
enigmatic. This multifaceted problem has arisen from the selectivity of pharmacological inhibitors
for Panxs and Cxs, methodological differences in assessing Panx and Cx function and the potential
compensation by other isoforms in gene silencing and genetic knockout models. Consequently,
there remains a void in the current understanding of speciﬁc contributions of Panxs and Cxs in
releasing ATP during homeostasis and disease. Differentiating the distinct signaling pathways that
regulate these two channels will advance our current knowledge of cellular communication and
aid in the development of novel rationally-designed drugs for modulation of Panx and Cx activity,
respectively.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. Open access under CC BY-NC-ND license. 1. Introduction
ATP has emerged as a prominent extracellular signaling mole-
cule inﬂuencing a diverse array of physiological and pathological
processes. By binding to purinergic receptors at the plasma mem-
brane of a cell, ATP and its metabolites (ADP, AMP and adenosine)
control a variety of intracellular signaling cascades, imparting
strict control over both intra- and intercellular communication in
a number of tissues. The biological relevance for adenine nucleo-
tides acting as autocrine/paracrine signaling molecules is evident
by the medley of purinergic receptor subtypes that are differen-
tially expressed across cell types, the extracellular expression of
nucleotidases whose activity ﬁne tunes the abundance of ATP out-
side of the cell and the ubiquitous presence of ATP in all cells in the
body, providing a pool of agonist for the initiation of purinergic sig-
naling cascades in all aspects of human physiology. Indeed, puri-
nergic signaling has been implicated in numerous physiologicalprocesses, including vascular tone and blood pressure regulation
[1–7], respiratory control [8–10], and neurotransmission [11–14],
as well as a number of pathologies including inﬂammation [15–
18], atherosclerosis [19,20], cancer [21–24], and neurological dis-
orders [25,26]. Two broad families of purinergic receptors have
been identiﬁed to date, termed P1 and P2 receptors (for an exten-
sive review on purinergic receptors see [27]). P1 receptors are G-
protein coupled receptors (GCPRs) that have a high binding afﬁnity
for the nucleoside adenosine and exist as 4 isoforms (A1, A2A, A2B
and A3). These receptors differentially couple to Gs or Gi and their
activation modulates the activity of adenylate cyclase and ulti-
mately intracellular cAMP levels. In contrast, the P2 receptors have
a high binding afﬁnity for ATP and ADP (as well as the uridine
nucleotides UTP and UDP) and are comprised of two subfamilies
denoted P2X and P2Y. The P2X receptor family contains 7 isoforms
(P2X1–7) which are classiﬁed as ligand-gated cation channels
whose activation regulates cellular membrane potential and intra-
cellular Ca2+ levels. The P2Y receptor family contains 8 isoforms
(P2Y1,2,4,6,11–14) which are metabotropic GPCRs that couple to
either Gq, Gs or Gi, in an isoform-speciﬁc manner, and their activa-
tion modulates intracellular inositol triphosphate (IP3), Ca2+ and
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agonist selectivity and cell and tissue speciﬁc expression proﬁles,
purinergic receptors are poised to selectively regulate distinct sig-
naling events both within and between cells throughout the body.
Another regulatory component in the purinergic signaling axis is
the expression and activity of extracellular enzymes that actively
degrade purine nucleotides, or ecto-nucleotidases. Two of these
enzymes ﬁne tune the abundance of ATP and its metabolites out-
side of the cell, with ecto-apyrase (CD39) acting to degrade extra-
cellular ATP and ADP to AMP and 50-ectonucleotidase (CD73)
converting AMP to adenosine [28]. It is now evident that the level
of expression and activity of these ecto-enzymes can differentially
regulate which family of purinergic receptor is activated when
extracellular purine concentration rises. As the expression or activ-
ity of CD39 increases, there is a shift in favor of P1 receptor activa-
tion as adenosine levels rise. Conversely, decreases in CD73 activity
will favor the activation of P2 receptors by shifting the extracellu-
lar purine pool from adenosine to ADP and ATP [29].
The ability of cells to orchestrate a variety of signaling cascades
in response to ATP has been well established, but the mechanisms
imparting control over the release of ATP from speciﬁc cell types
has become more controversial. In a cell type and context-depen-
dent manner, several mechanisms for ATP liberation have been
proposed, including vesicular release and channel-dependent
mechanisms, with connexin (Cx) hemichannels and pannexin
(Panx) channels being the most highly studied (reviewed in
[30,31]). These two families of membrane proteins form closed
channels at the cell surface that when activated, allow for the dif-
fusion of ions and small signaling molecules across the plasma
membrane, notably ATP. While multiple lines of evidence have
emerged implicating Cxs and Panxs in cellular ATP release, it has
been difﬁcult to clearly discriminate the contribution of each chan-
nel to this process in a myriad of cell types and tissues. These dis-
crepancies have limited our understanding of the importance of Cx
vs. Panx-dependent ATP release and have hindered the develop-
ment of selective agonist and antagonists to modulate the contri-
bution of these channels to purinergic signaling events. In order
to fully elucidate the (patho)physiological roles of Cx hemichan-
nels and Panx channels in correlation to ATP-driven cellular signal-
ing processes, it is imperative to characterize the innate differences
between these two channels and utilize this information for the
development of rationally-designed drugs to selectively target
each protein. To this end, this review is focused on the currently
understood differences between Cxs and Panxs at the molecular
and functional levels with an emphasis on the difﬁculties that
are faced in segregating Cxs and Panxs in ATP release; including
methodological differences between studies, the growing problem
of pharmacology and the potential compensation by other protein
isoforms. Additionally, emerging evidence that supports an inti-
mate link between receptor-dependent activation of Panx channels
vs. Cx hemichannels is addressed.
2. Similarities and differences between Cxs and Panxs
The connexins were ﬁrst described in the early 1970’s as the
principal proteins comprising intercellular gap junctions [32]. To-
day, more than 20 human isoforms have been identiﬁed, showing
differential tissue distribution and functional properties. These gap
junction proteins harbor four transmembrane domains with two
extracellular loops, intracellular N- and C-termini and a single
intracellular loop. Each extracellular loop contains three highly
conserved cysteine resides which form intramolecular disulﬁde
bridges that are thought to be critically important for stabilizing
the secondary structure of these domains and gap junction forma-
tion [33,34]. Connexin monomers hexamerize to form halfchannels, or hemichannels, that are trafﬁcked to the plasma mem-
brane and readily dock with unapposed hemichannels on adjacent
cells. This docking results in the formation of open gap junction
channels, providing a direct conduit for the transfer of current,
intracellular ions, second messengers and small molecules (up to
1 kD in size) between coupled cells, potentiating heterocellular
communication in many organ systems; notably the heart, vascu-
lature and brain [35–39]. As the concept of purinergic signaling
gained support and the search for candidate pathways to mediate
cellular ATP release ensued, it has been proposed that undocked
connexin hemichannels may provide a mode for conducted ATP re-
lease from cells. Based on previous observations that ATP can tra-
verse intact gap junction channels [40,41], and the strong
concentration gradient of ATP between the cytosol and extracellu-
lar milieu, opening of connexin hemichannels at the non-junc-
tional plasma membrane may favor ATP diffusion from the cell.
Congruently, with the aid of ectopic expression systems, electro-
physiology and bioluminescence-based assays for the quantiﬁca-
tion of ATP, several connexin isoforms have been reported to
form hemichannels capable of releasing ATP [42–45]. In particular,
the ubiquitous Cx43 isoform has been extensively studied in this
regard. The physiological and pathological roles for Cx hemichan-
nel activity have been reported in cell volume regulation, hearing,
sensory processing in the retina, cardiac ﬁbrosis, cerebral ischemia,
and inﬂammation [44–55]. While these observations lend credence
for an active role of Cx hemichannels outside of their primary func-
tion to form gap junctions, the experimental and biological condi-
tions required to open these hemichannels has relied, in large part,
on manipulating the cellular environment to more pathological
conditions. For example, experimental interrogation of Cx hemi-
channel activity and ATP release has depended greatly on over-
expressing connexins in unpaired cells and decreasing the
extracellular [Ca2+] to nearly zero. The latter approach has
stemmed from the observation that extracellular divalent cations
impart negative regulation on Cx hemichannels [56,57]. In addition
to decreasing [Ca2+]e below the physiological range, a number of
studies have reported Cx hemichannel activity following strong
depolarization beyond physiological membrane potentials (i.e.,
potentials >0 mV) [56,58–60]. As such, it is currently unclear
whether these experimental conditions mimic the normal physio-
logical context in which these hemichannels reside or whether
their contribution to purinergic signaling is more relevant in dis-
ease. Nonetheless, several recent studies have identiﬁed Cx hemi-
channel activity in the presence of physiological [Ca2+]e and at
resting membrane potentials, supporting the possibility that Cx
hemichannels function to regulate physiological signaling cascades
[61–66]. Speciﬁcally, recent evidence has indicated that endoge-
nous Cx43 hemichannels activate in response to mechanical stim-
ulation in isolated endothelial cells, which was reported to be
tightly regulated by RhoA GTPase and inﬂammatory mediators
[64]. In a separate study, Cx43 hemichannels were shown to be
activated in response to increased ﬂuid shear stress by a process
requiring direct coupling of the hemichannel to a5b1 integrins o
mechanical stress [63]. Additionally, Cx43 hemichannel activity in-
creases in response to changes in extracellular glucose concentra-
tions, potentially implicating their function in glucose sensing and
downstream metabolic signaling [61]. Hemichannels formed by
Cx26 have also been reported to open in response to increases in
the polyunsaturated fat linoleic acid, suggesting a possible role
for these channels in cell growth and audition [62]. Outside of
Cx43 and Cx26, the lens-speciﬁc connexin isoforms, Cx46 and
Cx50, have been shown to form functional hemichannels under
physiological conditions [60,67,68]. While these recent studies
are in support of Cx hemichannel function in a number of physio-
logical process, it remains unclear whether their contribution
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ATP release. In addition, while these studies may support a role for
Cx hemichannel activation under conditions of physiological
[Ca2+]e and membrane potentials, it remains to be determined
whether these functions are preserved in vivo. Outside their roles
in physiological ATP release, Cx hemichannels may provide a pat-
ent conduit for cellular ATP release during a number of pathologi-
cal conditions. Most notably, Cx37- and Cx43 hemichannel
mediated ATP release has been observed from monocytes and acti-
vated neutrophils during inﬂammation and atherosclerosis
[44,53,69]. Moreover, during ischemia, where there is a decrease
in [Ca2+]e, Cx hemichannels in astrocytes open releasing ATP and
glutamate, which potentiates neuronal excitotoxicity and cell
death [70].
More recently, a novel family of channel forming proteins
termed pannexins (Panx) has been identiﬁed [71]. Panxs are ortho-
logs of the invertebrate gap junction proteins, innexins, but do not
share signiﬁcant sequence homology to the Cxs. Three Panx iso-
forms have been identiﬁed to date (Panx1, Panx2 and Panx3), with
Panx1 being ubiquitously expressed, Panx2 expressed in the cen-
tral nervous system and Panx3 expressed in skin, bone and carti-
lage [72–75]. Despite the lack of sequence homology to Cxs,
Panxs share a similar membrane topology existing as tetraspan
membrane proteins with intracellular N- and C-termini. Like the
Cxs, the Panx1 and Panx3 isoforms oligomerize to form hexameric
single membrane channels, whereas Panx2 is predicted to exist in
higher order oligomers, notably heptamers and octomers [76,77].
Despite these similarities, Panxs do not form gap junction chan-
nels, but exist to solely function as single membrane channels
[78]. Currently, it is thought that discrete differences between
the extracellular loops of the Panxs, as compared to Cxs, might ac-
count for their inability to form cell-to-cell channels. While the Cxs
contain 6 conserved cysteine residues in their extracellular loops,
Panxs only harbor 4. The absence of two cysteines in these do-
mains may impart an unfavorable secondary structure or decrease
the stability of the extracellular loops on Panxs preventing gap
junction docking. An alternative explanation for the absence of
gap junction formation by Panxs may be due to the high amount
of glycosylation of their extracellular loops, which may sterically
hinder docking of Panx channels between cells [77,79,80]. Based
on these observations, Panx channels have become a prominent
candidate for cellular ATP release. Panx1 has been the most studied
of the three isoforms and electrophysiological and biochemical
analyses have revealed that Panx1 channels can activate and re-
lease ATP under normal physiological [Ca2+]e and favorable mem-
brane potentials (i.e., <0 mV), and in response to activation of a
number of receptors making them prime candidates for regulated
ATP release (discussed below) [7,81–88]. In this regard, Panx1
channels have been implicated in the regulation of vascular tone
and blood ﬂow, mucocilliary clearance in airway epithelia, cellular
apoptosis, inﬂammasome activation and neuronal cell death dur-
ing ischemia [7,81,82,89–92].
As our knowledge of the functional properties of Panx channels
and Cx hemichannels continues to grow and new technologies are
developed to aid in isolation of their respective functions in ATP re-
lease, the particular contribution of each channel to purinergic sig-
naling in health and disease will become evident and provide novel
therapeutic targets.
3. Current difﬁculties in segregating Cx- and Panx-dependent
ATP release
Differentiating the roles of Cx hemichannels and Panx channels
in cellular ATP release has been a difﬁcult problem to overcome.
These issues have been primarily associated with the lack of spec-iﬁcity of pharmacological blockers of the two channels, overlap-
ping expression in a number of cell types and tissues, the use of
different experimental approaches to assess channel function and
the potential issue of compensation by other isoforms in studies
employing genetic manipulation of Cx and Panx expression. Due
to these limitations in segregating Cx- and Panx-dependent activ-
ity in relation to ATP release, it has become increasingly difﬁcult
to ascribe unequivocal function to one channel over the other in
a number of physiological and pathological contexts. These limita-
tions are discussed below in detail.
4. Limitations in pharmacological selectivity for Cx
hemichannels and Panx channels
The study of Cx hemichannel and Panx channel function has re-
lied intently on the use of pharmacological inhibitors of channel
currents, dye uptake and ATP release. This review will focus on
the most commonly used pharmacological inhibitors of Cxs and
Panxs; for a comprehensive list of Panx and Cx inhibitors refer to
[93–95]. Notably, a number of gap junction blockers including ﬂu-
fenamic acid (FFA), the long-chain alcohols octonol and heptanol,
glycyrrhetinic acid (GA) derivatives (18a-GA and carbenoxolone
(CBX)) and mimetic peptides have been employed to inhibit Cxs.
Many of these substances have been reported to block both Cx
hemichannel and gap junction activity, which has limited the
interpretation of speciﬁc contribution of hemichannels vs. gap
junctions in cell-to-cell communication. For example, FFA, a potent
inhibitor of Cx based gap junctions, strongly reduces hemichannel
currents in unpaired Xenopus oocytes overexpressing Cx50 or Cx46
[96]. In addition, the GA derivative 18a-GA which prevents dye
coupling between cells paired by gap junctions, inhibits dye uptake
by Cx43 hemichannels in astrocytes [97]. Nonetheless, several of
these inhibitors have been assessed in their relative potency for
inhibition of Cx hemichannels and Panx channels. In terms of Cx
hemichannels, FFA, octonol and heptanol have been reported to
block gap junction and Cx hemichannel activity with minimal ef-
fect on Panx1 channels [96,98–100]. Comparatively, FFA has been
reported to inhibit Cx hemichannel activity at lowmicromolar con-
centrations, while analysis of the effects of this compound on
Panx1 channels expressed in oocytes showed only modest inhibi-
tion of Panx1 currents at 300 lM [100]. As Panxs have emerged
as possible candidate channels for ATP release, a number of these
inhibitors that were originally thought to selectively block Cx-
based gap junctions and hemichannels are now known to also
block Panx channels, in some cases to a much higher degree than
Cx hemichannels. This is best exempliﬁed by the GA derivative
CBX which inhibits both Cx hemichannels and Panx1 channels.
Pharmacological assessment of CBX potency has revealed a sub-
stantially greater afﬁnity for Panx1 channel inhibition than Cx
hemichannel inhibition (EC50 = 5 lM for Panx1 vs. 10–100 lM
for Cx43 hemichannels [97,100]). Based on these observations,
many previous studies employing CBX to block Cx hemichannel
function likely also blocked Panx1 function and as a result, it has
now become common to employ CBX as a Panx1 blocker. At the
other end of the spectrum, a few compounds have been identiﬁed
that are more speciﬁc for Panx channel inhibition than Cx hemi-
channel inhibition, notably the uricosuric drug probenecid. Pro-
benecid has been reported to block Panx1 currents and dye
uptake in oocytes expressing the channel, with no effect on cur-
rents carried by Cx46 or Cx32143 (a chimera of Cx32 containing
the ﬁrst extracellular loop of Cx43) [101]. In addition, probenecid
reduced [Ca2+]i in response to histamine in subcutaneous ﬁbro-
blasts which was dependent on Panx1-mediated ATP release [102].
As the problem of pharmacological selectivity for Cx hemichan-
nels and Panx channels has grown, novel methods for targeting
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peptides receiving major focus. Cx mimetic peptides were ﬁrst
developed to block gap junction formation and subsequent inter-
cellular communication and were widely used in model systems
where cellular conduction is essential including the heart [103],
lung epithelium [104], and vascular smooth muscle and endothe-
lial cells [105,106]. These peptides have been designed to mimic
the primary amino acid sequence of varying regions of Cx isoforms,
with the majority mimicking the extracellular loop regions. Fol-
lowing the observation that Cx mimetic peptides could inhibit
gap-junctional communication in coupled cells, presumably by
preventing docking of Cx hemichannels between cells, their ability
to selectively block Cx hemichannels was assessed. Of particular
note, the Cx mimetics Gap26 and Gap27 which mimic regions of
the ﬁrst and second extracellular domains of Cx43, respectively,
can inhibit currents carried by Cx43 hemichannels expressed in
HeLa cells [107,108]. Moreover, Gap26 has been reported to inhibit
ATP release from corneal endothelial cells in response to mechan-
ical stress and reduce basal ATP release from vascular endothelial
cells in culture [109,110]. While these studies initially advanced
the repertoire of pharmacological agents to selectively block Cx
hemichannels and gap junctions, recent evidence has emerged
indicating cross-inhibition of Panx1 channels by several Cx mi-
metic peptides. Most notably, the Gap26 and Gap27 peptides were
shown to inhibit Panx1 currents in oocytes as well as those carried
by Cx43 [111]. Moreover, the Cx mimetic peptide 32Gap24, which
mimics a sequence in the Cx32 intracellular loop domain, had no
effect on hemichannel currents from cells expressing the
Cx32143 chimera but drastically reduced Panx1 currents [111].
These observations may suggest that the mode of action of these
mimetic peptides is not dependent on the mimicked sequence, as
Panx1 does not share sequence homology in either its extracellular
loop or intracellular domains with Cxs. Based on the cross-inhibi-
tion observed with many of the currently employed connexins mi-
metic peptides, new efforts have been made to develop novel
peptide antagonists that may speciﬁcally inhibit Cx hemichannels
without affecting gap junction channels or Panx channels. Re-
cently, a novel Cx mimetic peptide termed Gap19 was developed,
mimicking a sequence in the intracellular loop of Cx43. Gap19
has been reported to speciﬁcally prevent Cx43 hemichannel activ-
ity in HeLa cell expressing exogenous Cx43 as well as endogenous
Cx43 currents in isolated cardiac myocytes through a mechanism
that disrupts intramolecular interactions between the intracellular
loop and C-tail of Cx43 [112]. This inhibition was selective for Cx43
hemichannels without affecting Panx1 channel currents or Cx40
hemichannel currents. In addition to Gap19, a secondmimetic pep-
tide designed to interrupt intracellular loop: C-tail interactions
called TAT-L2 has been reported to speciﬁcally inhibit endogenous
Cx43 hemichannel activity in endothelial cells and hemichannel
activity in ectopic expression systems [113]. These new peptides
have shed light on the gating of Cx43 hemichannels which appears
to be tightly regulated by interactions between the intracellular
domains of Cx43. Due to the increasing success of mimetic pep-
tides in targeting Cx hemichannls, a mimetic peptide of the ﬁrst
extracellular loop of Panx1 termed 10panx1 was developed and
has subsequently been shown to signiﬁcantly inhibits channel cur-
rents, dye uptake and ATP release mediated by Panx1 in a number
of cell types [114–116]. The Panx mimetic peptide has not escaped
the issue of cross-inhibition, however, as it was recently shown
that the 10panx1 peptide also blocks Cx46 hemichannel currents
[111].
Based on the sum of these observations, the study of Cx hemi-
channel and Panx channel function remains plagued by the over-
lapping pharmacology. As we continue to accumulate new
information on the relative potency of current and new drugs for
blockade of Panxs and Cxs, it will be important to not rely solelyon one inhibitor but to utilize a gamut of blockers at appropriate
concentrations to deﬁne the contributions of Cx hemichannels
and Panx channels to purinergic signaling events.5. Experimental methodologies in the study of Cx and Panx
function
In addition to the limitations in segregating Cx hemichannel
and Panx channel function pharmacologically, there is a discourse
in the methods utilized to interrogate each channel’s function as it
relates to ATP release. Currently, three techniques are commonly
employed to measure Cx and Panx activity: dye uptake or release,
electrophysiological preparations to measure channel currents and
strategies aimed at directly quantifying ATP liberation from cells.
Dye uptake assays have been used as a parameter of cell perme-
ability in response to a range of stimuli that evoke Cx hemichannel
or Panx channel opening. These assays rely on the ability of a dye
present in the extracellular milieu to cross the plasma membrane
and become concentrated inside of the cell and quantiﬁed by ﬂuo-
rescence microscopy. Some commonly used ﬂuorescent molecules
include Lucifer yellow, ethidium bromide, propidium iodide, DAPI,
YoPro-1 and ToPro-1 (e.g., [86,117,118]). Each of these molecules
has very distinct characteristics including differences in charge,
size and conformation which may speciﬁcally affect their respec-
tive permeabilities through Cx hemichannels or Panx channels. In
agreement, differences in the permeability of several of these dyes
through gap junctions and Cx hemichannels have been assessed in
HeLa cells expressing a number of different Cx isoforms (Cx26,
Cx31, Cx32, Cx40, Cx43 and Cx45) [119,120]. The results of these
studies indicate that speciﬁc Cx isoforms harbor differential per-
meabilities to speciﬁc ﬂuorescent molecules, likely based on the
relative charge or size of the permeant and conductance properties
of the gap junction or hemichannel. Based on these observations,
the selection of molecules for dye uptake experiments should be
considered carefully depending on the particular isoform being
studied [119]. Notwithstanding, dye uptake experiments have pro-
vided a strong output for quantifying the permeability of cells as it
relates to hemichannel or channel activation but this methodology
should not be solely relied on for the assessment of ATP release as
one is not indicative of the other.
Electrophysiology has been the workhorse for assessing Cx
hemichannel and Panx channel activity. These methods, coupled
with ectopic expression systems to isolate the channel of interest,
have provided great insight into the properties of both Cxs and
Panxs and aided in discerning the relative selectivity of pharmaco-
logical blockers for the two channels as discussed above. Whole-
cell and singe-channel recordings have identiﬁed a number of un-
ique properties between Cx hemichannels and Panx channels. Cx43
hemichannels expressed in oocytes show a conductance of
220 pS whereas Panx1 conductance has been initially reported
to be 500 pS [84,121]. Cx hemichannels have been shown to be
tightly regulated by membrane potential, with strong depolariza-
tions (+60 mV) activating the channel while Panx1 channels
can open under hyperpolarizing potentials in the physiological
range (>20 mV) [121,122]. Moreover, electrophysiological analy-
ses have revealed that both Cx43 hemichannels and Panx1 chan-
nels are permeable to ATP. Utilizing an ATP gradient between the
patch pipette and bath solution, Bao et al. demonstrated the direct
permeability of ATP through single Panx1 channels in excised
patches [84]. Similarly, whole cell and excised patch clamp tech-
niques have indicated conductance of ATP through hemichannels
composed of Cx43 [43]. These latter studies also employed dual
electrophysiological recordings and bioluminescence for simulta-
neous photo-detection of ATP in inside-out patches from Cx43
expressing oocytes, directly coupling the electrophysiological
Fig. 1. Panx3 is upregulated in the arterial wall of a global Panx1 knockout animal.
Immunocytochemical analysis of Panx1 and Panx3 expression in isolated mouse
thoracodorsal arteries (TDA). In wild type C57Bl/6 animals (top panels) Panx1 is
abundantly expressed in the endothelial and smooth muscle cells, with minimal
Panx3 expression detected. Parallel analysis of Panx3 expression in isolated TDA
from a global Panx1 knockout mouse (Panx1/) revealed a dramatic upregulation
of Panx3 when Panx1 was genetically ablated (lower panels). Asterisks indicate the
blood vessel lumen. Nuclei are stained with DAPI (blue) and autoﬂuorescence of the
internal elastic lamina is in green. Scale bar = 10 lm.
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implement of electrophysiology in the study of Cx hemichannel
and Panx channel function has signiﬁcantly advanced our knowl-
edge on the unique properties of these two families of channels,
there remain limitations in extrapolating these functional studies
to the physiological setting. As mentioned above, many of the
observations implicating Cx hemichannels and Panx channels
activity in ATP release have relied on ectopic expression systems
to isolate the channel from contaminating signals. Thus, these
channels are placed in an artiﬁcial setting that may not reﬂect their
endogenous environment. Given these considerations, future stud-
ies aimed at assigning Cx hemichannel or Panx channel activity to
ATP release should make effort to analyze these channel properties
in native cells. Nonetheless, the knowledge we have gained on the
biophysical properties of Cxs and Panxs through the use of electro-
physiological techniques has made great strides in differentiating
between the two families of proteins.
Assessment of the contribution of Cx hemichannels and Panx
channels to cellular ATP release should not depend on dye uptake
and electrophysiological recordings alone, but employ assays for
the direct detection of ATP liberated from the cell. The current
gold-standard for ATP quantiﬁcation relies on luciferin:luciferase
chemistry where the enzyme luciferase catalyzes the oxidation of
ATP and luciferin ultimately resulting in the generation of a photon
which can be readily quantiﬁed by luminometry. Luciferin:lucifer-
ase bioluminescence has subsequently been implemented in a
number of models to directly test the accumulation of extracellular
ATP in response to Cx hemichannel and Panx channel activation
[43,81,82,88,109,123].
The aforementioned methods currently used for assessing Panx
channel and Cx hemichannel activity as it relates to ATP release
and purinergic signaling have shed light on the properties of these
two channels and have provided direct evidence that both Cx
hemichannels and Panx channels are permeable to ATP. It is impor-
tant to note that not all studies are created equally, with experi-
mental conditions and outputs differing between groups. Based
on these points, future studies geared towards assigning function
to one channel over another should strive to implement a combi-
nation of these methods.
6. Potential for compensation in genetic knockdown and
knockout models
The advent of RNA interference and knockout animal models
has led to great advances in the study of Cx hemichannels and Panx
channels. In combination with pharmacological characterization of
channel activity and ATP release, the targeted reduction or deletion
of Cx and Panx isoforms has revealed speciﬁc contributions of each
channel to physiological and pathological ATP release. In particu-
lar, genetic knockout of Cx43 from murine neutrophils was shown
to suppress hemichannel-dependent ATP release from these cells
under inﬂammatory conditions [44]. Similarly, deletion of the
Cx37 isoform in monocytes abolishes ATP release and promotes
atherosclerotic plaque development [53]. In these studies, hemi-
channel activity was clear as these inﬂammatory cells do not form
gap junctions. Since the discovery of the pannexin family, a num-
ber of genetic knockout mouse models have been developed to as-
sess the role of these channels in various physiological and
pathological conditions, with much focus placed on ischemic in-
jury. Due to the increasingly evident role for Panx1 channels in
neuronal ischemia, global Panx1 knockout mice have been as-
sessed for their susceptibility to ischemic damages that accompany
stroke. Interestingly, a study by Bargiotas et al. reported that mice
lacking both Panx1 and Panx2 isoforms are protected from ische-
mic brain injury and have reduced Panx channel activity in
their cortical neurons [124]. In another study, both global andneuron-speciﬁc deletion of Panx1 prevented ischemic insult to
retinal ganglion cells by eliminating Panx1-dependent membrane
permeation and interleukin-1b processing [125].
It is evident from these studies that genetic manipulation of Cxs
and Panxs in vivo can have dramatic effects on a number of pathol-
ogies. However, in some cases, the phenotype of genetically mod-
iﬁed animals does not reﬂect what has been established using
other model systems. One potential reason for this discrepancy is
the possibility of altering the expression of other related isoforms
that may either compensate for the function of the lost protein
or, conversely, contribute to the resulting phenotype. This has been
well exempliﬁed in the vasculature where genetic deletion of
endothelial Cx37 caused a related decrease in Cx40 expression in
the mouse aortic endothelium [126]. A similar effect was observed
in mice lacking Cx40 expression, where Cx37 was also downregu-
lated. In contrast, Cx40 knockout mice exhibited a dramatic in-
crease in Cx37 and Cx43 expression in the medial smooth muscle
cells [126]. In a related study, Cx40 knockout mice showed a redis-
tribution and decrease of Cx43 in aortic endothelial cells, suggest-
ing that these two isoforms are regulated in a similar fashion [127].
To assess the possible role for compensation of Panx isoforms in
the vasculature, we have performed immunocytochemical labeling
for Panx1, Panx2 and Panx3 on isolated thoracodorsal arteries from
a global Panx1 knockout mouse generated by Genentech. In this
study, Panx1 expression was undetectable in the endothelial and
smooth muscle layers of Panx1 knockout mice as compared to
the robust expression observed in wild type mice. Examination of
the effect of global Panx1 knockout on the other two Panx isoforms
revealed that Panx3, which is not normally expressed by the cells
in the blood vessel wall was dramatically upregulated and readily
detected in both smooth muscle and endothelium (Fig. 1). These
puzzling ﬁndings may point towards a compensatory mechanism
by which Panx3 is up-regulated to fulﬁll the role of Panx1. Compar-
ison of the sequences between the three Panx isoforms has also
indicated that Panx1 and Panx3 have higher sequence homology
than Panx2 [80]. In addition, Panx3 channels have been reported
to release ATP, placing these channels as possible candidates to
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provocative and may point towards coordinated regulation of
Panxs it remains unclear whether these two families of proteins
share regulatory elements at the transcriptional and post-tran-
scriptional levels.
7. Coupling Panx channels to receptor activation
Panx channels and Cx hemichannels have emerged as promi-
nent regulators of cellular ATP release, as described above, and
much effort has focused on determining the molecular basis for
how each of these channels can be activated. There are a number
of biological cues that have shed light on the particular circum-
stances in which Cx hemichannels and Panx channels open. Cx
hemichannels have been reported to open in response to ischemia
and subsequent decreases in [Ca2+]e and pH (increased CO2), as
well as in response to hypotonic stress, mechanical stimulation
and strong membrane depolarizations. Panx1 channel activation
has been implicated in response to a number of the same factors
including ischemia, low O2 tension, hypotonic stress and mechan-
ical stimulation; however, their activation has also been reported
in response to caspase-cleavage of the Panx1 C-tail and depolari-
zations in the physiological range. The comparison of Cx hemi-
channel vs. Panx channel mediated ATP release over the past
10 years has brought about intriguing evidence that Panx channel
activation (Panx1 in particular) may be tightly coupled to plasma
membrane receptors in a number of cell types and biological pro-
cesses. To date, however, knowledge on similar regulation of Cx
hemichannels by receptor activation has not been reported. The
current evidence for Cx hemichannel-mediated ATP release points
toward a role for these channels during pathological conditions
such as ischemia and inﬂammation, pathologies that are often
associated with decreases in [Ca2+]e and large ﬂuctuations in
membrane potential. While Panx channels have also been
implicated in these pathological states, there is an accumulationFig. 2. Mechanisms of activation of connexins hemichannels and pannexin channels.
hemichannels and Panx channels. Cx hemichannels activate in response to a number of re
concentrations, mechanical stimulation, hypotonicity and strong membrane depolarizat
stimuli, including ischemic stress, caspase cleavage of their intracellular C-tails, lowere
connexins hemichannels, Panx channels open in response to activation of a number of me
N-methyl-D-aspartate receptors (NMDAR) as well as metabotropic P2Y1, P2Y2 and P2
a1D-adrenergic receptors (a1D-AR) and protease activated receptor-1 (PAR-1).of evidence that they release ATP under physiological conditions
in response to the activation of several receptor types. Among
these receptors are purinergic P2X(4/7) [85,91,128] and P2Y(1/2/6)
[129,130] receptors, bradykinin B2 receptors (BDKRB2) [131], his-
tamine H1 receptors (HRH1) [102], a1D-adrenergic receptors (a1D-
AR) [7,132], protease activated receptor 1 (PAR-1) [88] and N-
methyl-D-aspartate receptors (NMDA) [90] (Fig. 2).
The involvement of purinergic receptors in the promotion of
Panx1-mediated ATP release has been most evident during inﬂam-
mation and inﬂammasome activation. The inﬂammasome is a mul-
tiprotein complex containing caspase enzymes whose activation
signals processing and secretion of the inﬂammatory cytokine IL-
1b [133]. Recent studies have suggested that activation of the
P2X7 receptor orchestrates inﬂammasome activation through the
induction of a large pore formed by Panx1 channels. [91,134–
136]. This signaling axis involves coupling of P2X7 receptors to
Panx1 channels that when activated may release ATP and allow
the inﬂux of other small ions which is required for caspase-1 pro-
cessing and IL-1b release in macrophages, neurons and other im-
mune cells [85,91]. Though Panx1 channels were originally
thought to form the sole large pore permeation pathway during
prolonged P2X7 receptor activation, several studies have emerged
indicating the existence of a separate conductance pathway inde-
pendent of Panx1 channels [137,138]. Another recently identiﬁed
regulator or this complex is the P2X4 receptor. The P2X4 receptors
has been shown to forming a complex with P2X7 and Panx1, func-
tioning to promote reactive oxygen species generation and en-
hance inﬂammasome activation [128]. It is currently unknown
whether ATP released from Panx1 channels in this complex serves
to amplify signaling through P2X7 and P2X4 receptors, or whether
the primary function of the Panx1 channels resides as an inﬂux
pathway for extracellular ions. Additionally, the Panx1 channel
has been shown to be negatively regulated by extracellular ATP,
providing a feedback mechanism for tight control of channel
activity, which may suggest that the ATP liberated from Panx1Schematic illustrating the receptor-dependent and independent activation of Cx
ceptor-independent cues including ischemic stress, decreased extracellular calcium
ions. Panx channels also activate in response to a number of receptor-independent
d oxygen tension and physiological depolarizations. In addition, and unique from
mbrane receptors including the ionotropic P2X4 and P2X7 purinergic receptors and
Y6 receptors, bradykinin B2 receptors (BDKRB2), histamine H1 receptors (HRH1),
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from chronic ATP release and apoptosis [139].
In addition to P2X receptors, a number of P2Y receptor isoforms
have been reported to induce Panx1 channel activation. Speciﬁ-
cally, the P2Y1 and P2Y2 isoforms, when expressed together with
Panx1 channels in oocytes, activate Panx1 channel currents in re-
sponse to ATP [129]. It was also reported that increases in cytoplas-
mic [Ca2+] positively regulate Panx1 channel activity in these cells
and the downstream signaling through P2Y receptors may induce
Panx1 activation through a calcium-dependent mechanism. More
recently, Panx1 activation downstream of P2Y6 receptor activation
was shown to promote ATP release from urothelial cells which pro-
motes bladder overreactivity [130]. Given the strong correlation
between purinergic receptor activation and Panx1-dependent
ATP release, certain cell types may utilize an ATP-induced ATP re-
lease pathway for cellular communication.
Along with the P2Y receptors mentioned above, several GPCRs
have been coupled to activation of Panx1 channels. Activation of
the BDKRB2 with bradykinin causes an increase in intracellular cal-
cium that has been reported to be downstream of ATP release from
Cxhemichannels and Panx1 channels in human subcutaneousﬁbro-
blasts [131]. In this study the authors report that blocking Cx
hemichannel activity with 2-octanol, reduced a portion of the bra-
dykinin-induced intracellular calcium event, but did not measure
the effect of Cx hemichannel blockers on ATP release in response
to bradykinin. In support of a role for Panx1 channel-mediated
ATP release in these cells, blockade of Panx1 channels with 10panx1
signiﬁcantly attenuated ATP release. In addition, removal of extra-
cellular calcium in these studies did not affect the magnitude of
ATP release. Since Cx hemichannels open in response to decreases
in [Ca2+]e, ATP release should increase under these conditions, un-
less all Cx hemichannels in these cells were already open, which
would be extremely detrimental to cell viability. A separate study
from the same group has reported that in addition to activation of
BDKRB2, Panx1 channels can also be activated in human subcutane-
ous ﬁbroblasts by histamine acting through the HRH1 [102].
In the vasculature, receptor coupling to Panx1 channels have
been observed in both smooth muscle and endothelial cells. In pri-
mary human umbilical vein endothelial cells, cell activation with
the protease thrombin causes signiﬁcant release of ATP into the
extracellular milieu [88]. The effects of thrombin on this process
were subsequently shown to be mediated by direct activation of
PAR-1 expressed on these endothelial cells, leading to a rise in intra-
cellular calciumand downstreamactivation Panx1 channels liberat-
ingATP.At the level of vascular smoothmuscle, Panx1channelshave
been linked to vasoconstriction in response toa1D-AR activation [7].
a1D-ARs receive sympathetic input fromperivascular nerves that re-
lease the AR agonist norepinephrine (NE). Binding of NE to the a1D-
ARs promotes Panx1 channel activation releasing ATP that then
binds to purinergic receptors located on the same or neighboring
VSMCs ultimately causing vasoconstriction in resistance arteries
[7,132]. In these studies, overexpression (utilizing a Panx1 plasmid)
or knockdown of Panx1 with targeted siRNAs strengthened and re-
duced a1D-AR mediated vasoconstriction, respectively.
Finally, Panx1 channel activation has been observed down-
stream of NMDAR activation in pyramidal neurons in response to
ischemia [89,90]. During conditions of cerebral ischemia, a period
of anoxic depolarization ensues in hippocampal neurons that is
promoted by the opening of Panx1 channels leading to excitotoxic-
ity and cell death [89,140]. These initial observations by Thompson
et al. supported a functional role for Panx1 channels in anoxic
depolarization in isolated hippocampal neurons, but have since
been debated in an in situ brain slice model [141]. This latter study
was unable to identify a discernable role for Panx1 channels during
ischemic insult in isolated hippocampal brain slices using a phar-
macological approach to block Panx channel activity. However,more recent evidence from Weilinger et al. utilizing a conditional
Panx1 knockout mouse model demonstrated a signiﬁcant role for
Panx1-mediated currents in ischemia-induced anoxic depolariza-
tions [90]. This event is mediated by activation of NMDARs ex-
pressed at the neuronal synapse which promotes activation of
Src Family Kinases (SFKs) and Panx1 channels. Using a novel com-
peting peptide designed against a region of the Panx1 C-tail that
contains a potential tyrosine phosphorylation site, as well as a
pharmacological inhibitor of SFKs called PP2, Weilinger et al. iden-
tiﬁed a speciﬁc role for SFKs in promoting Panx1 channel activity
during ischemia [90]. In sum, the growing evidence for activation
of a number of receptors imparting activation of Panx1 channels
may suggest that this is a deﬁning difference between Cx hemi-
channel and Panx1 channels.
8. Conclusions
Deﬁning particular roles for Cx hemichannels and Panx channels
in cellular ATP release has been an enduring problem in the ﬁeld of
purinergic signaling. These two families of channel forming proteins
share a number of similarities, despite lacking sequence homology,
which have hindered the development of speciﬁc inhibitors to test
their function, respectively. While there are apparent similarities,
such as membrane topology, plasma membrane localization and
functional overlap as channels capable of releasing ATP, Cxs and
Panxs appear to harbor unique characteristics affecting channel for-
mation, gating and activation. Importantly, the Panxs have emerged
as physiological ATP release channels while the role of Cx hemichan-
nels under physiological settings in not clear. Ascribing a particular
function to Panxs vs. Cxs in health and disease remains a difﬁcult
problem and is associateswith factors including the pharmacological
selectivity between channels, methodological differences in assess-
ing channel function and genetic alterations associated with knock-
out animal models. Great strides have been made in many of these
areas, particularly at the genetic level with the advent of inducible,
cell-type speciﬁc knockout animals. In addition, more rigorous phar-
macological approaches are being employed in combinationwith ge-
netic models to increase the accumulation of evidence for the
involvement of Cx hemichannels and Panx1 in many physiological
and pathological contexts. As we continue to assign new roles for
Panxs and Cxs in ATP release, it will remain important to not rely
on a single technique for ascribe function to one channel or the other,
but to employ a rigorous examination of channel function through
multiple assays. Finally, as research on Panx channels has continued
to grow, it is becoming increasingly evident that these channels may
be intimately linked to receptor activation in many cell types and
tissues, providing a unique segregation from Cx hemichannels.
Future studies will be important to elucidate the potential for Cx
hemichannel to release ATP under physiological conditions in re-
sponse to speciﬁc receptor activation. In conclusion, despite the cur-
rent limitations, there is still much to learn about the unique
properties between Cx hemichannels and Panx channels and their
respective roles in human physiology and disease.Acknowledgments
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